Note 2 - Summary of Significant Accounting Policies - Segment Reporting (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|||
Revenues | $ 212 | $ 93 | $ 355 | $ 175 | ||||
Cost of revenues | 14 | 16 | 25 | 21 | ||||
Acquired in-process research and development | 1,848 | 0 | 1,967 | 0 | ||||
Research and development expense | 155 | 81 | 258 | 118 | ||||
Interest income | (3) | (7) | (21) | (40) | ||||
Change in fair value of royalties payable due to related parties | 1,667 | 1,504 | 2,830 | 1,590 | ||||
Income tax benefit | (950) | 0 | (1,674) | 0 | ||||
Segment net loss | (5,458) | $ (4,045) | (4,220) | $ (2,675) | (9,503) | (6,895) | ||
Operating Segments [Member] | ||||||||
Revenues | 212 | 93 | 355 | 175 | ||||
Cost of revenues | 14 | 16 | 25 | 21 | ||||
Acquired in-process research and development | 1,848 | 0 | 1,967 | 0 | ||||
Depreciation and amortization expense | 529 | 526 | 1,060 | 1,048 | ||||
Stock-based compensation expense | 98 | 13 | 189 | 19 | ||||
Salaries and benefits expense | 1,310 | 1,060 | 2,624 | 1,721 | ||||
Professional fees | 317 | 374 | 1,044 | 1,046 | ||||
Research and development expense | 155 | 81 | 258 | 118 | ||||
Interest income | (3) | (7) | (21) | (40) | ||||
Interest expense | 67 | 5 | 116 | 8 | ||||
Change in fair value of royalties payable due to related parties | 1,667 | 1,504 | 2,830 | 1,590 | ||||
Change in fair value of trading debt securities | (10) | 0 | (10) | 0 | ||||
Income tax benefit | (950) | 0 | (1,674) | 0 | ||||
Other segment items (1) | [1] | 628 | 741 | 1,450 | 1,539 | |||
Segment net loss | (5,458) | (4,220) | (9,503) | (6,895) | ||||
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] | ||||||||
Segment net loss | $ 0 | $ 0 | $ 0 | $ 0 | ||||
|
X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. No definition available.
|
X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition The amount of in-process research and development expense acquired. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|